Structure via PubChem · Public domain (PubChem)
tazemetostat
Sign in to saveAlso known as E-7438, EPZ 6438, EPZ-6438, EPZ6438
Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).
In the Vinony graph
Within Vinony's link graph, tazemetostat is referenced by 279 other articles, and connects out to neoplasm, tiazofurin and cancer.
Vinony files it under Antineoplastic drugs, Cancer treatments and Chemotherapy.
Its subject is documented across 7 Wikipedia language editions.
Chemical data
- Formula
- C34H44N4O4
- Molecular weight
- 572.7 g/mol
- IUPAC name
- N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide
- SMILES
- CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5
- InChIKey
- NSQSAUGJQHDYNO-UHFFFAOYSA-N
- XLogP
- 4.2
- Polar surface area
- 83.1 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- neoplasm of mature B-cells, diffuse large B-cell lymphoma, lymphoma, mesothelioma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 572.336256
- Has use
- medication
Show 2 more facts
- chemical formula
- C₃₄H₄₄N₄O₄
- canonical SMILES
- CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5
via Wikidata · CC0
~4 min read
Encyclopedic overview
3 sectionsContents
- History
- References
- External links
Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).
The most common side effects are pain, fatigue, nausea, decreased appetite, vomiting and constipation. People taking tazemetostat are at increased risk of developing secondary malignancies including: T-cell lymphoblastic lymphoma (a type of blood cancer that affects the lymphatic system usually found in the lymph nodes), myelodysplastic syndrome (a disorder resulting from poorly formed or dysfunctional blood cells) and acute myeloid leukemia (a cancer of the blood and bone marrow).
Excerpted from Wikipedia’s “tazemetostat” article, available under the CC BY-SA 4.0 licence.